A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Decitabine (Primary) ; GO 203 2c (Primary)
  • Indications Myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 23 Feb 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
    • 21 May 2016 The protocol has been amended with the addition of the drug Decitabine and hence the treatment table and primary endpoint has been changed to evaluate the MTD of the combination (GO-203-2c + Decitabine)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top